SCHEMBL928538

SCHEMBL928538

Cc1noc(-c2ccccc2)c1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.54
PTPN1 P18031 1/20 0.53
ALDH1A1 P00352 5/20 0.51
MAPT P10636 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KDM4E B2RXH2 2/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
TRPA1 O75762 1/20 0.47
LPAR1 Q92633 1/20 0.47
LPAR3 Q9UBY5 1/20 0.47
TP53 P04637 2/20 0.46
IP6K1 Q92551 2/20 0.46
IP6K3 Q96PC2 2/20 0.46
IP6K2 Q9UHH9 2/20 0.46
HSD17B10 Q99714 1/20 0.46
BRD4 O60885 2/20 0.46
BRD2 P25440 1/20 0.46
NR1I2 O75469 1/20 0.46
GAA P10253 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19119250 0.98 PTGS1 (0.53) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL13508 0.97 PTGS1 (0.51) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL15280716 0.88 RAB9A (0.52) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL4676416 0.88 PTGS1 (0.53) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL5533717 0.86 KMT2A (0.58) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL11128848 0.86 PTGS1 (0.51) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL22467553 0.86 ALDH1A1 (0.46) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL893014 0.86 PTGS1 (0.51) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL14789796 0.86 RAB9A (0.51) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL6710243 0.86 PTGS1 (0.51) PTGS1PTPN1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6869953-B2 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents HOFFMAN-LA ROCHE INC. (US) 2005-03-22 US claimed
US-20040192744-A1 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents HAAG RAINER (DE) 2004-09-30 US claimed
US-20030139404-A1 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2003-07-24 US claimed
CN-122036713-A Quinoline derivative compound and preparation method and application thereof 东北农业大学 2026-05-15 CN disclosed
CN-117430609-A Purine derivative compound, preparation method and application thereof 东北农业大学 2024-01-23 CN disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed
US-9695183-B2 Substituted 7-azabicycles and their use as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2017-07-04 US disclosed
US-9637496-B2 Substituted 7-azabicycles and their use as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2017-05-02 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
WO-2004004720-A1 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-01-15 WO disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed
US-20030114505-A1 Novel isoxazole and thiazole compounds and use thereof as drugs KYOWA HAKKO KIRIN CO., LTD. (JP) 2003-06-19 US disclosed
WO-2003015780-A2 ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE NOVARTIS AG (CH) 2003-02-27 WO disclosed
EP-1258484-A1 NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS KIRIN BEER KABUSHIKI KAISHA (JP) 2002-11-20 EP disclosed
US-6458960-B1 ANTICANCER AGENTS, RHEUMATIC DISEASES AND ANTIINFLAMMATORY AGENTS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2002-10-01 US disclosed
US-6180796-B1 TUBULIN POLYMERIZATION INHIBITORS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2001-01-30 US disclosed
EP-0990645-A1 NOVEL SULFONAMIDE DERIVATIVES Nippon Kayaku Kabushiki Kaisha (JP) 2000-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192744-A1 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents NAT1, CYP1A1, UGT1A1 PTGS1 772/4885PTPN1 330/4885ALDH1A1 198/4885
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 PTGS1 1583/4885PTPN1 3692/4885ALDH1A1 4193/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 PTGS1 1823/4885PTPN1 3323/4885ALDH1A1 4421/4885
US-20030114505-A1 Novel isoxazole and thiazole compounds and use thereof as drugs LPAR3, LPAR1, LPAR4 PTGS1 1203/4885PTPN1 278/4885ALDH1A1 1093/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 PTGS1 1583/4885PTPN1 3692/4885ALDH1A1 4193/4885
US-20030139404-A1 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents NAT1, CYP1A1, UGT1A1 PTGS1 772/4885PTPN1 330/4885ALDH1A1 198/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 PTGS1 1159/4885PTPN1 1702/4885ALDH1A1 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.